∙Net profit up 45.9% YoY at Rs 383 cr. ∙Revenue up 5.5% YoY at Rs 1,777.8 cr.
∙Lupin gets USFDA approval for Fluconazole tablets to market a generic equivalent of Diflucan tablets of Pfizer. ∙This product will be manufactured at Lupin’s Pithampur facility in India.
∙Future Consumer appoints Samson Samuel as Managing Director with effect from Oct 23, 2023 for 3 years.
Swipe up to